注射用紫杉醇(白蛋白结合型)联合光动力疗法治疗晚期非小细胞肺癌致中心气道狭窄的临床效果  

Clinical effect of Paclitaxel for Injection(Albumin Bound)combined with photodynamic therapy for the treatment of central airway stenosis caused by advanced non-small cell lung cancer

作　　者：牛建明[1] 赵晨茜 张旭宇[1] 赵薇[1] 许雪林 李润浦 NIU Jianming;ZHAO Chenxi;ZHANG Xuyu;ZHAO Wei;XU Xuelin;LI Runpu(The Second Department of Respiratory and Critical Care Medicine,Baoding No.2 Central Hospital,Baoding 072750,Hebei,China)

机构地区：[1]保定市第二中心医院呼吸与危重症医学二科,河北省保定市072750

出　　处：《广西医学》2023年第8期916-922,共7页Guangxi Medical Journal

基　　金：河北省保定市科技计划项目(2041ZF031)。

摘　　要：目的探讨注射用紫杉醇(白蛋白结合型)联合光动力疗法治疗晚期非小细胞肺癌(NSCLC)致中心气道狭窄的临床效果及安全性。方法将60例晚期NSCLC致中心气道狭窄患者随机分为观察组与对照组,每组30例。对照组采用光动力疗法治疗,观察组在对照组基础上采用注射用紫杉醇(白蛋白结合型)化疗。于对照组治疗后42 d、观察组治疗2个化疗周期后,评价近期疗效和安全性。比较两组治疗前后气道狭窄情况、欧洲癌症研究与治疗组织生命质量核心量表(EORTC QLQ-C30)评分及肺功能,以及两组远期生存情况。结果治疗后,观察组的客观缓解率和疾病控制率(分别为40.0%、76.6%)均高于对照组(分别为16.7%、50.0%),气道狭窄段最小直径大于对照组,气道狭窄程度轻于对照组,用力肺活量、第1秒用力呼气容积、最大自主通气量及EORTC QLQ-C30中的躯体功能、疼痛、呼吸困难和整体生存质量评分均优于对照组,中位无进展生存期和中位总生存期均长于对照组(均P<0.05)。治疗期间两组患者的不良反应均可控制,整体耐受性良好。结论注射用紫杉醇(白蛋白结合型)联合光动力疗法治疗晚期NSCLC致中心气道狭窄的总体疗效确切,不仅能有效解除患者气道狭窄,改善肺通气功能,提高生存质量,而且可使患者在远期生存方面获益,患者耐受性好。Objective To investigate the clinical effect and safety of Paclitaxel for Injection(Albumin Bound)combined with photodynamic therapy for the treatment of central airway stenosis caused by advanced non-small cell lung cancer(NSCLC).Methods Totally 60 patients with central airway stenosis caused by advanced NSCLC were randomly divided into observation group or control group,with 30 cases in each group.Patients in the control group received photodynamic therapy,while patients in the observation group received chemotherapy of Paclitaxel for Injection(Albumin Bound)on the basis of the control group.The short-term efficacy and safety were evaluated in the control group 42 days after treatment and in the observation group after two cycles of chemotherapy.The pre-and post-treatment airway stenosis situation,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30-Item Core Instrument(EORTC QLQ-C30)score and lung function,as well as the long-term survival were compared between the two group.Results After treatment,the objective response rate and disease control rate of the observation group(40.0%and 76.6%,respectively)were higher than those of the control group(16.7%and 50.0%,respectively);furthermore,the observation group yielded larger minimum diameter of the airway stenotic segment,lower degree of airway stenosis,and superior forced vital capacity,forced expiratory volume in one second and maximal voluntary ventilation,as well as superior scores of physical functioning,pain,dyspnea and overall quality of life in EORTC QLQ-C30,and longer median progression-free survival time and median total survival time as compared with the control group(all P<0.05).During treatment,the adverse reactions of both groups were controllable,and the overall tolerance was favorable.Conclusion Paclitaxel for Injection(Albumin Bound)combined with photodynamic therapy exerts a definite overall efficacy for the treatment of central airway stenosis caused by advanced NSCLC.It not only can effectively alleviate

关 键 词：晚期非小细胞肺癌 中心气道狭窄 注射用紫杉醇(白蛋白结合型) 光动力疗法 远期生存 安全性 

分 类 号：R734.2[医药卫生—肿瘤]